Yes, these were in 2022 with stents. Might see it heat up again with reimbursement no longer a major risk (and if anything, substantially better for canaloplasty now than for stents). Of course, for any acquiror the more data the better so bids are often made soon after results are released by companies.
iTrack Advance must look incredibly cheap to these acquirors...
Yes, these were in 2022 with stents. Might see it heat up again...
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.10M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $45.70K | 217.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2722 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 57356 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |